James Marken - ANI Pharmaceuticals Senior Development
| ANIP Stock | USD 55.86 0.76 1.38% |
Executive
Mr. James G. Marken is Senior Vice President, Operations and Product Development of the Company, since may 2016. He had served as ANIPs Vice President, Operations and Product Development, since March 2009. He has served as the Companys Vice President, Operations, since June 2013 and was promoted to Senior Vice President, Operations and Product Development in May 2016. Mr. Marken joined ANIP in March 2007 as General Manager of the Minnesota facilities. As Senior Vice President, Operations and Product Development, Mr. Marken was principally responsible for the following areas manufacturing, packaging, engineeringmaintenance, purchasing, warehousing and product development. Mr. Marken brings over 30 years of pharmaceutical industry experience to the Company. Prior to joining ANIP in March 2007, he worked for Solvay Pharmaceuticals as plant manager and in various departments including quality control, validation and manufacturing since 2016.
| Age | 61 |
| Tenure | 8 years |
| Address | 210 Main Street West, Baudette, MN, United States, 56623 |
| Phone | 218 634 3500 |
| Web | https://www.anipharmaceuticals.com |
James Marken Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Marken against ANI Pharmaceuticals stock is an integral part of due diligence when investing in ANI Pharmaceuticals. James Marken insider activity provides valuable insight into whether ANI Pharmaceuticals is net buyers or sellers over its current business cycle. Note, ANI Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell ANI Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Marken over three months ago Disposition of 7250 shares by James Marken of ANI Pharmaceuticals at 49.51 subject to Rule 16b-3 | ||
James Marken over three months ago Disposition of 5300 shares by James Marken of ANI Pharmaceuticals at 57.06 subject to Rule 16b-3 | ||
James Marken over six months ago Disposition of 3653 shares by James Marken of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 |
ANI Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0125 % which means that it generated a profit of $0.0125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.016) %, meaning that it created substantial loss on money invested by shareholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/21/2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.07. At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 11/21/2024, Liabilities And Stockholders Equity is likely to grow to about 949.6 M, while Non Current Liabilities Other is likely to drop slightly above 14.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Andrew Davis | Ironwood Pharmaceuticals | 37 | |
| Einat Zehavi | INC Research Holdings | N/A | |
| MP MBA | Amphastar P | N/A | |
| Bhethanabottla Phanimitra | Dr Reddys Laboratories | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Anil Namboodiripad | Dr Reddys Laboratories | 54 | |
| Jose Vieira | Procaps Group SA | 58 | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| David Boyer | Neurocrine Biosciences | 45 | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Kristen JD | Pacira BioSciences, | 50 | |
| Ronald Silver | Ironwood Pharmaceuticals | 41 | |
| Omri Batzir | INC Research Holdings | N/A | |
| Declan OConnor | Alkermes Plc | N/A | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Susan Mesco | Pacira BioSciences, | N/A | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
Management Performance
| Return On Equity | -0.016 | ||||
| Return On Asset | 0.0125 |
ANI Pharmaceuticals Leadership Team
Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth JD, Chief Disease | ||
| Stephen Carey, CFO, Vice President | ||
| Krista Davis, Senior Officer | ||
| Muthusamy RPh, COO RD | ||
| Thomas Rowland, Senior Brands | ||
| Nikhil Lalwani, CEO President | ||
| Meredith Cook, General VP | ||
| Chad Gassert, Senior Strategy | ||
| James Marken, Senior Development | ||
| Ori Gutwerg, Senior Generics | ||
| Meredith JD, General VP | ||
| Christopher Mutz, Senior Disease | ||
| Mary MD, Chief Officer |
ANI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ANI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.016 | ||||
| Return On Asset | 0.0125 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 1.67 B | ||||
| Shares Outstanding | 21.02 M | ||||
| Shares Owned By Insiders | 11.10 % | ||||
| Shares Owned By Institutions | 99.57 % | ||||
| Number Of Shares Shorted | 2.16 M | ||||
| Price To Earning | 43.35 X |
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against ANI Stock
| 0.54 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.45 | VRDN | Viridian Therapeutics | PairCorr |
| 0.36 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.